Symposium overview: Genetic polymorphisms in DNA repair and cancer risk

Jennifer Hu, H. W. Mohrenweiser, D. A. Bell, S. A. Leadon, M. S. Miller

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

A symposium, Genetic Polymorphisms in DNA Repair and Cancer Risk, was presented at the 40th Annual Meeting of the Society of Toxicology, held in San Francisco, California, in March 2001. A brief report of the symposium was published (Kaiser, Science 292, 837-838, 2001). Molecular epidemiological studies have shown that polymorphic variants of genes involved in the metabolism and repair of carcinogens can act as cancer susceptibility genes. These variants of drug metabolic and DNA-repair enzymes either increase the activation of chemical carcinogens or decrease the cells' ability to detoxify/repair mutagenic damages. Although on an individual basis these variant alleles may only slightly change catalytic activity and increase cancer risk, their polymorphic frequency in the human population may contribute to a high proportion of cancer cases. Studies conducted over the past few years have identified variant alleles for a number of DNA-repair genes, some of which have been shown to change DNA-repair capacity. Identifying these genotypic alterations in DNA-repair enzymes and their association with cancer may help to elucidate the mechanisms of cancer etiology and to predict both disease risk and response to cancer therapy, since most antineoplastic treatments mediate their effects through DNA damage.

Original languageEnglish
Pages (from-to)64-73
Number of pages10
JournalToxicology and Applied Pharmacology
Volume185
Issue number1
DOIs
StatePublished - Dec 17 2002
Externally publishedYes

Fingerprint

Genetic Polymorphisms
Polymorphism
DNA Repair
Repair
DNA
DNA Repair Enzymes
Genes
Neoplasms
Carcinogens
Alleles
San Francisco
Metabolism
Neoplasm Genes
Antineoplastic Agents
Catalyst activity
DNA Damage
Chemical activation
Association reactions
Epidemiologic Studies
Pharmaceutical Preparations

Keywords

  • Cancer risk
  • DNA repair
  • SNPs

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Symposium overview : Genetic polymorphisms in DNA repair and cancer risk. / Hu, Jennifer; Mohrenweiser, H. W.; Bell, D. A.; Leadon, S. A.; Miller, M. S.

In: Toxicology and Applied Pharmacology, Vol. 185, No. 1, 17.12.2002, p. 64-73.

Research output: Contribution to journalArticle

Hu, Jennifer ; Mohrenweiser, H. W. ; Bell, D. A. ; Leadon, S. A. ; Miller, M. S. / Symposium overview : Genetic polymorphisms in DNA repair and cancer risk. In: Toxicology and Applied Pharmacology. 2002 ; Vol. 185, No. 1. pp. 64-73.
@article{a1d8eefc742b475c9b008c92cfff2996,
title = "Symposium overview: Genetic polymorphisms in DNA repair and cancer risk",
abstract = "A symposium, Genetic Polymorphisms in DNA Repair and Cancer Risk, was presented at the 40th Annual Meeting of the Society of Toxicology, held in San Francisco, California, in March 2001. A brief report of the symposium was published (Kaiser, Science 292, 837-838, 2001). Molecular epidemiological studies have shown that polymorphic variants of genes involved in the metabolism and repair of carcinogens can act as cancer susceptibility genes. These variants of drug metabolic and DNA-repair enzymes either increase the activation of chemical carcinogens or decrease the cells' ability to detoxify/repair mutagenic damages. Although on an individual basis these variant alleles may only slightly change catalytic activity and increase cancer risk, their polymorphic frequency in the human population may contribute to a high proportion of cancer cases. Studies conducted over the past few years have identified variant alleles for a number of DNA-repair genes, some of which have been shown to change DNA-repair capacity. Identifying these genotypic alterations in DNA-repair enzymes and their association with cancer may help to elucidate the mechanisms of cancer etiology and to predict both disease risk and response to cancer therapy, since most antineoplastic treatments mediate their effects through DNA damage.",
keywords = "Cancer risk, DNA repair, SNPs",
author = "Jennifer Hu and Mohrenweiser, {H. W.} and Bell, {D. A.} and Leadon, {S. A.} and Miller, {M. S.}",
year = "2002",
month = "12",
day = "17",
doi = "10.1006/taap.2002.9518",
language = "English",
volume = "185",
pages = "64--73",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Symposium overview

T2 - Genetic polymorphisms in DNA repair and cancer risk

AU - Hu, Jennifer

AU - Mohrenweiser, H. W.

AU - Bell, D. A.

AU - Leadon, S. A.

AU - Miller, M. S.

PY - 2002/12/17

Y1 - 2002/12/17

N2 - A symposium, Genetic Polymorphisms in DNA Repair and Cancer Risk, was presented at the 40th Annual Meeting of the Society of Toxicology, held in San Francisco, California, in March 2001. A brief report of the symposium was published (Kaiser, Science 292, 837-838, 2001). Molecular epidemiological studies have shown that polymorphic variants of genes involved in the metabolism and repair of carcinogens can act as cancer susceptibility genes. These variants of drug metabolic and DNA-repair enzymes either increase the activation of chemical carcinogens or decrease the cells' ability to detoxify/repair mutagenic damages. Although on an individual basis these variant alleles may only slightly change catalytic activity and increase cancer risk, their polymorphic frequency in the human population may contribute to a high proportion of cancer cases. Studies conducted over the past few years have identified variant alleles for a number of DNA-repair genes, some of which have been shown to change DNA-repair capacity. Identifying these genotypic alterations in DNA-repair enzymes and their association with cancer may help to elucidate the mechanisms of cancer etiology and to predict both disease risk and response to cancer therapy, since most antineoplastic treatments mediate their effects through DNA damage.

AB - A symposium, Genetic Polymorphisms in DNA Repair and Cancer Risk, was presented at the 40th Annual Meeting of the Society of Toxicology, held in San Francisco, California, in March 2001. A brief report of the symposium was published (Kaiser, Science 292, 837-838, 2001). Molecular epidemiological studies have shown that polymorphic variants of genes involved in the metabolism and repair of carcinogens can act as cancer susceptibility genes. These variants of drug metabolic and DNA-repair enzymes either increase the activation of chemical carcinogens or decrease the cells' ability to detoxify/repair mutagenic damages. Although on an individual basis these variant alleles may only slightly change catalytic activity and increase cancer risk, their polymorphic frequency in the human population may contribute to a high proportion of cancer cases. Studies conducted over the past few years have identified variant alleles for a number of DNA-repair genes, some of which have been shown to change DNA-repair capacity. Identifying these genotypic alterations in DNA-repair enzymes and their association with cancer may help to elucidate the mechanisms of cancer etiology and to predict both disease risk and response to cancer therapy, since most antineoplastic treatments mediate their effects through DNA damage.

KW - Cancer risk

KW - DNA repair

KW - SNPs

UR - http://www.scopus.com/inward/record.url?scp=18744381537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744381537&partnerID=8YFLogxK

U2 - 10.1006/taap.2002.9518

DO - 10.1006/taap.2002.9518

M3 - Article

C2 - 12460738

AN - SCOPUS:18744381537

VL - 185

SP - 64

EP - 73

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 1

ER -